FLT3 and acute myeloid leukemia: We analyzed the in vivo effect of CPZ on primary AML cells from 19 patients (Age 17–81, median 48, male/female 12/7), including AML cells with FLT3 WT/KIT WT (ten cases), FLT3 ITD (eight cases), and KIT D816V (one case) (Supplementary Table 1).